NOVO NORDISK A S Business Summary

Novo Nordisk A/S (NONOF) operates a high-margin pharmaceutical business model centered on the discovery, development, and global distribution of chronic disease therapies. The company generates the vast majority of its revenue—approximately 94% as of early 2026—through its Diabetes and Obesity Care segment, which leverages a portfolio of blockbuster GLP-1 receptor agonists including Ozempic, Rybelsus, and Wegovy. A secondary Biopharmaceuticals segment focuses on rare disease areas such as hemophilia and growth hormone disorders. Despite its historical dominance, the company enters 2026 facing a strategic reset characterized by a projected 5-13% decline in sales and operating profit. This contraction is driven by unprecedented U.S. pricing pressures, including a "Most Favored Nations" agreement and the launch of a federal direct-to-consumer channel, alongside intense competition from Eli Lilly, Roche, and emerging biotech rivals like Viking Therapeutics and Structure Therapeutics. While Novo Nordisk remains a market leader, its obesity market share has recently compressed to approximately 40-51% as it pivots toward oral formulations and next-generation combinations like CagriSema to defend its position. Leadership is currently spearheaded by President and CEO Maziar "Mike" Doustdar, who assumed the role in August 2025 after a decade-long tenure as EVP of International Operations where he doubled regional sales. He is supported by CFO Karsten Munk Knudsen and Chief Scientific Officer Martin Holst Lange, the latter of whom oversees a newly consolidated R&D unit designed to accelerate cardiometabolic innovation. The company’s governance is anchored by Board Chair Lars Rebien Sørensen, a former Novo Nordisk CEO (2000–2016) who was re-appointed to steer the firm through its current competitive transformation. Novo Nordisk maintains a unique ownership structure, controlled by the Novo Nordisk Foundation through its holding company, Novo Holdings A/S, which remains the primary shareholder. The company traces its pedigree back to the 1923 founding of Nordisk Insulinlaboratorium by Nobel laureate August Krogh and Marie Krogh, and the 1925 founding of Novo Terapeutisk Laboratorium by the Pedersen brothers, entities that merged in 1989 to form the modern global powerhouse.